Colorectal Cancer Clinical Trials in Los Angeles

Showing 101-120 of 287 trials

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more

Elicio Therapeutics25 participantsStarted Oct 2021

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +7 more locations

TERMINATED< 1 mile

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

NCT03765736

This trial screens patients with colon or rectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) for genetic mutations for recommendation to a molecularly assigned therapy. Identifying gene mutations may help patients enroll onto target companion trials that target these mutations.

Metastatic Colon AdenocarcinomaMetastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8+17 more

Academic and Community Cancer Research United199 participantsStarted Apr 2020

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +15 more locations

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Colorectal Cancer Trials in Other Cities

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 2 Study of DKN-01 in Colorectal Cancer

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

A Study to Investigate LYL845 in Adults With Solid Tumors

Stage II/III Colorectal Cancer Recurrence

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Other Conditions in Los Angeles